Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Anavex
Biotech
Anavex stock sinks 30% as lead asset fails in Rett syndrome
Anavex’s lead asset has failed to significantly improve disease characteristics in a pediatric Rett syndrome trial.
Gabrielle Masson
Jan 2, 2024 12:08pm
Fierce Biotech's Rotten Tomatoes of 2022
Dec 19, 2022 3:00am
After changing study goals, Anavex touts Rett syndrome win
Feb 1, 2022 11:26am
Annovis' Alzheimer's drug fails to improve dementia symptoms
Jul 28, 2021 8:00pm
Ipsen pays $28M upfront for IRLAB's Phase 2b Parkinson's drug
Jul 15, 2021 2:05pm
Anavex's neuro drug slows decline in Parkinson's disease
Jun 28, 2021 1:08pm
